Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 1032 • ACR Convergence 2020
Epidemiology and Geographic Evaluation of ANCA-associated Vasculitis (AAV) at a Rural Academic Health Center Utilizing an Electronic Health Record (EHR)
Eva Rottmann¹, Jason Bankert², Andrea Berger², Lester Kirchner², Joseph Dewalle², Marissa Meissner³, Jason George², Ion Dan Bucaloiu², Jaya Prakash Sugunaraj², Sudheer Penupolu² and David Bulbin¹, ¹Geisinger Health System, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Geisinger Medical Center, Danville
Background/Purpose: ANCA-associated vasculitis has a reported prevalence ranging from 3.2 to 9.1 cases per 100,000 individuals, but little is known of geographic variations. The aim of…
Abstract Number: 1438 • ACR Convergence 2020
Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)
Jason Springer¹ and Ryan Funk², ¹University of Kansas Medical Center, Overland Park, KS, ²UNIVERSITY OF KANSAS, Kansas City, KS
Background/Purpose: Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, has been shown to be an effective maintenance therapy for granulomatosis with polyangitiis (GPA) and microscopic polyangiitis…
Abstract Number: 1417 • ACR Convergence 2020
Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study
Sara Thietart¹, Guillaume Beinse², Perrine Smets³, Alexandre Karras⁴, Carole Philipponnet⁵, Jean-François Augusto⁶, Khalil El Karoui⁷, Rafik Mesbah⁸, Dimitri Titeca Beauport⁹, Mohamed Hamidou¹⁰, Pierre-Louis Carron¹¹, Julien Campagne¹², Karim Sacre¹³, Pascal Cohen¹, Eric Liozon¹⁴, Claire Blanchard-Delaunay¹⁵, Alex Kostianovsky¹⁶, Christian Pagnoux¹⁷, Luc Mouthon¹, Loïc Guillevin¹⁸, Benjamin Terrier¹ and Xavier Puéchal for the French Vasculitis Study Group¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ²Inserm UMR 1138, Centre de Recherche des Cordeliers, Paris, France, ³Department of Internal Medicine, Centre Hospitalier Universitaire Clermont-Ferrand Hôpital Gabriel-Montpied, Clermont Ferrand, France, ⁴Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France, ⁵Department of Nephrology, CHU Clermont-Ferrand, Clermont-Ferrand, Clermont Ferrand, France, ⁶Department of Nephrology-Dialysis-Transplantation, CHU Angers, Angers, France, ⁷Department of Nephrology and Transplantation, Hôpital Universitaire Henri-Mondor, Creteil, France, ⁸Department of Nephrology, CH Boulogne-sur-Mer, Boulogne-Sur-Mer, France, ⁹Department of Nephrology, Amiens University Medical Center, Amiens, France, ¹⁰Department of Internal Medicine, Hôtel-Dieu, CHU Nantes, Nantes, France, ¹¹Department of Nephrology-Dialysis-Transplantation, CHU Grenoble-Alpes, Grenobles, France, ¹²Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ¹³Département de Médecine Interne, Hôpital Bichat, APHP, Paris, France, ¹⁴Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, ¹⁵Department of Internal Medicine, CH, Niort, France, ¹⁶Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Buenos Aeres, Argentina, ¹⁷Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁸Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France
Background/Purpose: ANCA-associated vasculitis (AAV) frequently occurs among older patients, with different clinical presentations than the younger. Little is known on the outcome of older patients…
Abstract Number: 1439 • ACR Convergence 2020
Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis
Alvise Berti¹, Sophie Hillion², Marta Casal Moura¹, Amber Hummel¹, Eva Carmona¹, Tobias Peikert¹, Carol Langford³, Peter A. Merkel⁴, Paul Monach⁵, Philip Seo⁶, Robert Spiera⁷, Eugene St Clair⁸, Fernando C. Fervenza¹, Kristina Harris⁹, John H. Stone¹⁰, Jacques-Olivier Pers¹¹, Ulrich Specks¹ and Divi Cornec¹², ¹Mayo Clinic, Rochester, MN, ²Brest University, Brest, Bretagne, France, ³Cleveland Clinic, Moreland Hills, OH, ⁴Division of Rheumatology University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's, Boston, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁸Duke University, Durham, NC, ⁹Immune Tolerance Network, Bethesda, MD, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹University of Brest, Brest, France, ¹²Rheumatology Department, Brest University Hospital, Brest, France
Background/Purpose: In ANCA-associated vasculitis (AAV) B cells play a central pathogenic role and are instrumental for the production of ANCA, which are thought to mediate…
Abstract Number: 1418 • ACR Convergence 2020
Clinical Presentations and Follow-up Results of Granulomatosis with Polyangiitis: An Analysis of 8 Years Clinical Experience with 220 Patients from a National Referral Center
Seyed Behnam Jazayeri¹, Farzaneh Kianifar², Samira Alesaeidi², Soheil Tavakolpour³, Amir Teimourpour⁴ and Sasan Dabiri², ¹Tehran university of medical scienses, Tehran, Iran, ²Tehran university of medical sciences, Tehran, Iran, ³Dana-faber cancer institute, Harvard Medical School, Boston, MA, ⁴Department of epidemiology and bio-statistics, Tehran university of medical sciences, Tehran, Iran
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a rare and life-threatening autoimmune disease. Due to the extremely low prevalence of GPA, monitoring of clinical characteristics and…
Abstract Number: 1440 • ACR Convergence 2020
The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis
Matthew Terrill¹, Hendrik Nel², Yassmin Musthaffa³, Wong Richard⁴, Ross Francis⁵, David Johnson⁵, Greg Keir⁶, David Gillis⁷ and Ranjeny Thomas⁸, ¹University of Queensland Diamantina Institute and Princess Alexandra Hospital, Rheumatology Department, Brisbane- Australia, Moffat beach, Queensland, Australia, ²University of Queensland Diamantina Institute, Brisbane, Queensland, Australia, ³University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Immunology Department, Princess Alexandra Hospital, Brisbane- Australia, Brisbane, Australia, ⁵Renal Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁶Respiratory Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁷Immunopathology Department, Royal Women’s and Children’s Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁸University of Queensland Diamantina Institute and Rheumatology Department, Princess Alexandra Hospital, Brisbane – Australia., Brisbane, Australia
Background/Purpose: In Myeloperoxidase (MPO) Anti Neutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (MPO-AAV), murine and human studies suggest that the MPO435-465 region, which includes ANCA-binding MPO447-459, the…
Abstract Number: 1419 • ACR Convergence 2020
Clinical Disease Might Be Divided into Two Phenotypes in ANCA Associated Vasculitis; Results of a Cluster Analysis
Elif Ediboglu¹, Onay Gercik², Emre Bilgin³, Dilek Solmaz⁴, Irfan Ocal⁵, Arzu Saglam⁶, Zeki Soypacacı², Haluk Cinaklı⁵, Sedat Kiraz³, Ömer Karadağ⁷ and Servet Akar², ¹Izmir Katip Celebi University, Izmir, Izmir, Turkey, ²Izmir Katip Celebi University, Izmir, Turkey, ³Hacettepe University, Ankara, Turkey, ⁴Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ⁵Izmir Katip Celebi University, Izmir, ⁶Hacettepe University, Ankara, ⁷Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara,, Ankara, Turkey
Background/Purpose: One of the controversial matters in ANCA associated vasculitis is the definition of disease based on clinical characteristics since there is a remarkable overlap…
Abstract Number: 1589 • ACR Convergence 2020
An Initiative to Improve Timely Glucocorticoid Tapering in Vasculitis
Arielle Mendel¹, Daniel Ennis², Shirley Lake³, Simon Carette⁴ and Christian Pagnoux⁵, ¹Division of Rheumatology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada, ³Division of Rheumatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Vasculitis guidelines recommend scheduled glucocorticoid (GC) tapering to avoid toxicity. In an audit of 130 consecutive new patients on GC assessed in our tertiary…
Abstract Number: 1420 • ACR Convergence 2020
Characterization of ANCA-Associated Vasculitis Among African American Patients
Sehris Khawaja¹, Saloni Godbole¹, Maryann Kimoto², Virginia Steen³ and Kaitlin Quinn⁴, ¹Georgetown University, Washington, DC, ²UCLA, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴National Institutes of Health, Washington, DC
Background/Purpose: ANCA-associated vasculitis (AAV) comprises a group of disorders characterized by inflammation of small and medium-sized arteries. Prevalence and phenotype of these diseases appear to…
Abstract Number: 1590 • ACR Convergence 2020
Bone Health in ANCA – Associated Vasculitis Patients
Deepa Ragesh Panikkath¹, Sandy Lee² and Christina Downey², ¹Loma Linda University Health, Department of Rheumatology, Loma Linda, CA, ²Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Glucocorticoids (GC) are an important mode of therapy in ANCA associated vasculitis (AAV), and osteoporosis (OP) and fractures are potential adverse effects seen. The…
Abstract Number: 1421 • ACR Convergence 2020
Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans
Luis Palomino¹, Angelo Gaffo², Sebastian Sattui³ and Dongmei Sun², ¹University of Alabama at Birmingham Hospital, Birmingham, AL ²University of Alabama at Birmingham, Birmingham, AL, ³Hospital for Special Surgery, New York, NY
Background/Purpose: ANCA-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA), affect mostly Caucasians of European descent. Clinical…
Abstract Number: 2048 • ACR Convergence 2020
Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis
Valerie Benard¹, Cynthia Farhat², Melissa Zarandi-Nowroozi², Madeleine Durand³, Christian Pagnoux⁴, Pierre Charles⁵, Xavier Puechal⁶, Loïc Guillevin⁷ and Jean-Paul Makhzoum¹, ¹Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Internal Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada, ²Department of Medecine, University of Montreal, Montreal, QC, Canada, ³Department of Internal Medicine, Centre Hospitalier de l’Universite de Montreal (CHUM) and Centre de Recherche du Centre Hospitalier de l’Universite de Montreal (CRCHUM), Montreal, QC, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁷Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France
Background/Purpose: Organ or life-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two of the antineutrophil cytoplasm antibody-associated vasculitis (AAV), are treated with cyclophosphamide or…
Abstract Number: 1422 • ACR Convergence 2020
Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data
Zachary Wallace¹, Xiaoqing Fu², John Stone³, Hyon Choi⁴ and Rochelle Walensky², ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Concord, MA, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: ANCA-associated vasculitis (AAV) leads to complications that contribute to poor quality of life and survival. Systemic vasculitis is associated with high healthcare utilization but…
Abstract Number: 2050 • ACR Convergence 2020
Autoantibodies Targeting Complement Receptors C3aR and C5aR1 Are Decreased in ANCA-associated Vasculitis and Correlate with a Higher Relapse Rate
Sebastian Klapa¹, Antje Müller², Andreas Koch³, Anja Kerstein-Staehle⁴, Wataru Kaehler³, Harald Heidecke⁵, Susanne Schinke⁶, Markus Huber-Lang⁷, Martin Nitschke⁸, Silke Pitann⁹, Christian Karsten¹⁰, Gabriela Riemekasten¹¹ and Peter Lamprecht², ¹University of Lübeck and Institute of Experimental Medicine, Christian-Albrechts-University of Kiel c/o German Naval Medical Institute, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ³Institute of Experimental Immunology, Christian-Albrechts-University Kiel, c/o German Naval Medical Institute, Kronshagen, Germany, ⁴University of Lübeck, Dept Rheumatology and Clinical Immunology, Luebeck, Germany, ⁵CellTrend GmbH, Luckenwalde, Germany, ⁶University of Lübeck, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, ⁷Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, Ulm, Germany, ⁸Department of Internal Medicine I, Transplant Center, University of Lübeck, Luebeck, Germany, ⁹University of Lübeck, Department of Rheumatology and Clinical Immunology,, Luebeck, Germany, ¹⁰Institute of Systemic Inflammation Research, University of Lübeck, Luebeck, Germany, ¹¹University of Lübeck, Department of Rheumatology and Clinical Immunology,, Lübeck, Germany
Background/Purpose: Activation of the alternative and common terminal complement pathways has been shown in ANCA-associated vasculitis (AAV). Circulating titers of the anaphylatoxin C5a are increased…
Abstract Number: 1424 • ACR Convergence 2020
Outcomes of Hospitalizations for Acute Myocardial Infarction in Patients with ANCA Associated Vasculitis from the National Inpatient Sample
Atefeh Vafa¹, Marielys Figueroa Sierra¹, Omid Behnamfar², Hamayon Babary¹, Suraiya Afroz¹ and Yih Chang Lin³, ¹University of South Florida, Tampa, FL, ²University of California San Diego, La Jolla, CA, ³University of South Florida, Morsani College of Medicine, Tampa, FL
Background/Purpose: Several studies in the past have shown significantly increased risks of cardiovascular disease in patients with ANCA associated vasculitis (AAV). This association is thought…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].